EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSPFOG00000000553
Gene Symbol: ATP1B1
3 Cross references
217 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSPFOG00000004729
Gene Symbol: ATP1B2
1 Cross references
174 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSPFOG00000005974
Gene Symbol: ATP1B2B
1 Cross references
202 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2b

Ensembl ID : ENSPFOG00000006028
Gene Symbol: ATP1B2B
1 Cross references
202 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSPFOG00000016854
Gene Symbol: ATP1B3
3 Cross references
236 Possible Orthologues:

Atr Serine/threonine Kinase

Ensembl ID : ENSPFOG00000013382
Gene Symbol: ATR
1 Cross references
205 Possible Orthologues:

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSPFOG00000015514
Gene Symbol: AXL
2 Cross references
187 Possible Orthologues:

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPFOG00000007387
Gene Symbol: BRAF
3 Cross references
219 Possible Orthologues:

Bcl2 Apoptosis Regulator

Ensembl ID : ENSPFOG00000005254
Gene Symbol: BCL2
3 Cross references
176 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSPFOG00000002526
Gene Symbol: BCL2L1
1 Cross references
226 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSPFOG00000015465
Gene Symbol: BCL2L1
4 Cross references
216 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSPFOG00000023090
Gene Symbol: BCL2L10
3 Cross references
128 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).